Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Myriad Genetics (MYGN) Return on Capital Employed (2016 - 2025)

Historic Return on Capital Employed for Myriad Genetics (MYGN) over the last 15 years, with Q3 2025 value amounting to 0.76%.

  • Myriad Genetics' Return on Capital Employed fell 6300.0% to 0.76% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.76%, marking a year-over-year decrease of 6300.0%. This contributed to the annual value of 0.13% for FY2024, which is 1200.0% up from last year.
  • According to the latest figures from Q3 2025, Myriad Genetics' Return on Capital Employed is 0.76%, which was down 6300.0% from 0.65% recorded in Q2 2025.
  • In the past 5 years, Myriad Genetics' Return on Capital Employed registered a high of 0.12% during Q3 2022, and its lowest value of 0.76% during Q3 2025.
  • In the last 5 years, Myriad Genetics' Return on Capital Employed had a median value of 0.17% in 2021 and averaged 0.24%.
  • Its Return on Capital Employed has fluctuated over the past 5 years, first soared by 1700bps in 2024, then tumbled by -6300bps in 2025.
  • Quarter analysis of 5 years shows Myriad Genetics' Return on Capital Employed stood at 0.17% in 2021, then grew by 22bps to 0.13% in 2022, then plummeted by -97bps to 0.26% in 2023, then skyrocketed by 47bps to 0.14% in 2024, then plummeted by -447bps to 0.76% in 2025.
  • Its last three reported values are 0.76% in Q3 2025, 0.65% for Q2 2025, and 0.14% during Q1 2025.